MedPage Today August 1, 2024
Joyce Frieden

— But the interim report was criticized by business owners and the PBM trade group

Pharmacy benefit managers (PBMs) often reimburse their own affiliated pharmacies at higher rates than they do independent pharmacies, to the disadvantage of insurers as well as taxpayers, the Federal Trade Commission (FTC) said.

“We see evidence PBMs pay their own pharmacies inflated prices,” said Suzie Jing of the FTC’s Office of Policy Planning, who presented interim results from the agency’s report on PBMs at a commission meeting Thursday. For example, she said, in the case of generic abiraterone (Zytiga) for prostate cancer, “it costs $229 to buy the drug, but the big three PBMs pay their affiliated pharmacies about $6,000 per month on average. That’s...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Govt Agencies, Pharma, Pharma / Biotech, Survey / Study, Trends
Key Trends in the Evolution of PBMs and Their Future Impact on Drug Pricing and Pharmacy Operations
Healthcare leaders urge Congress to recognize pharmacists as providers
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Trump tariffs could drive up generic drug costs: 5 takeaways
Bridging the Gap: Pharmacists' Role in Advancing Pharmacogenomic Testing Standards

Share This Article